Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New paradigms for therapy for osteosarcoma.

Rajaram Nagarajan1, Denis Clohisy, Brenda Weigel

  • 1Pediatric Epidemiology and Clinical Research, University of Minnesota, Mayo Mail Code 484, 420 Delaware Street SE, Minneapolis, MN 55455, USA. nagar003@umn.edu

Current Oncology Reports
|October 14, 2005
PubMed
Summary

New osteosarcoma therapies are emerging for young patients. This review explores promising immune-based treatments, tumor growth inhibitors, and novel chemotherapies to improve survival rates for this bone cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026
Same author

Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

JCO precision oncology·2025
Same author

Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration.

European journal of cancer (Oxford, England : 1990)·2025
Same author

New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis.

The Lancet. Oncology·2025
Same author

Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Long-term kidney outcomes in survivors of Wilms tumor: a single-center retrospective cohort study.

Pediatric nephrology (Berlin, Germany)·2025

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Bone Cancer Research

Background:

  • Osteosarcoma is a primary bone cancer predominantly affecting adolescents and young adults.
  • While survival for non-metastatic osteosarcoma has improved to approximately 70%, metastatic or recurrent disease carries a poor prognosis with only 20% long-term survival.
  • There is a critical need for novel therapeutic strategies to address the challenges posed by advanced osteosarcoma.

Purpose of the Study:

  • To review and summarize emerging therapeutic developments for osteosarcoma.
  • To highlight novel treatment modalities currently under investigation.
  • To provide an overview of potential future directions in osteosarcoma management.

Main Methods:

  • Literature review of recent advancements in osteosarcoma treatment.

Related Experiment Videos

  • Analysis of preclinical and clinical data for new therapeutic agents.
  • Synthesis of information on immune-based therapies, tumor growth inhibition, radiotherapy, and novel chemotherapies.

    • Main Results:

    • Several promising new therapies are in development for osteosarcoma.
    • These include advancements in immunotherapy, targeted therapies aimed at inhibiting tumor growth, refined radiotherapy techniques, and novel chemotherapeutic agents.
    • The review consolidates information on these diverse approaches.

    Conclusions:

    • Emerging therapies offer new hope for improving outcomes in osteosarcoma patients, particularly those with metastatic or recurrent disease.
    • Continued research and clinical trials are essential to translate these developments into improved patient survival.
    • A multi-modal approach incorporating novel agents may enhance the efficacy of osteosarcoma treatment.